Modern treatment methods help to prolong and improve the lives of comorbid patients

Every year, combined pathologies become an increasingly pressing medical problem, complicating treatment and worsening the condition of patients. At the V All-Russian Forum, general practitioners discussed how to prevent and combat complications of common diseases.

Every third patient over 50 years of age has 2–3 concomitant diseases^[1]. This complicates the course of each disease and affects approaches to therapy. For example, comorbidity slows down the recovery process after COVID-19 infection.

One of the treatment options for patients with pulmonary symptoms after COVID-19 is Longidaza^®. Long-Cov-III-21 study^[2] demonstrated that the drug increased the proportion of patients with a 10% increase in forced vital capacity, and also helped reduce the occurrence of common post-Covid symptoms such as fatigue and malaise after exercise.

Another respiratory pathology that is aggravated by comorbidity is pneumococcal infection. Past pneumonia, often caused by pneumococcus, affects the health of older people, increasing the likelihood of developing cardiovascular disease, dementia and other cognitive disorders, and increasing the likelihood of death within a year^[3][4].

Despite a large number of scientific studies^[5], confirming a reduction in overall mortality due to immunization of the population against pneumococcal infection, vaccination coverage of the adult population in the country remains low.

Another pathology, which in 60% of cases is combined with or provokes the development of other pathologies, is osteoarthritis^[6][7].

Physical therapy, diet and modern complex treatments help reduce the level of inflammation in osteoarthritis. A number of clinical studies have demonstrated a significant symptomatic effect of native collagen in osteoarthritis . Results of recent studies of the Artneo^®complex, which includes undenatured type II collagen, showed a reduction in pain, stiffness and an improvement in functional state of joints and quality of life of patients with osteoarthritis after just 2 months of use.